{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:01:44Z","timestamp":1787896904068,"version":"build-2784847793"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejpb.2024.114239","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T22:35:05Z","timestamp":1709678105000},"page":"114239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Preparation of etoposide liposomes for enhancing antitumor efficacy on small cell lung cancer and reducing hematotoxicity of drugs"],"prefix":"10.1016","volume":"198","author":[{"given":"Ruixue","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damao","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114239_b0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.thorsurg.2021.04.011","article-title":"Is small cell lung cancer a surgical disease at the present time?","volume":"31","author":"Loizidou","year":"2021","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.ejpb.2024.114239_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejpb.2024.114239_b0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1183\/09031936.00105009","article-title":"Treatment of extensive-stage small cell lung carcinoma: current status and future prospects","volume":"35","author":"Demedts","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejpb.2024.114239_b0020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2024.114239_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156234","article-title":"Etoposide: A rider on the cytokine storm","volume":"168","author":"Bailly","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.ejpb.2024.114239_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115676","article-title":"Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: A comprehensive review","volume":"259","author":"Fathi-Karkan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2024.114239_b0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0009-9236(95)90158-2","article-title":"A population model for the leukopenic effect of etoposide","volume":"57","author":"Karlsson","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2024.114239_b0040","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.1991.9.8.1480","article-title":"Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity","volume":"9","author":"Ratain","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2024.114239_b0045","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.1994.12.11.2390","article-title":"Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation","volume":"12","author":"Rodman","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2024.114239_b0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2024.114239_b0055","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jconrel.2020.07.036","article-title":"Dimeric prodrug-based nanomedicines for cancer therapy","volume":"326","author":"Li","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114239_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606628","article-title":"Rational design of cancer nanomedicine: nanoproperty integration and synchronization","volume":"29","author":"Sun","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejpb.2024.114239_b0065","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1002\/app.38107","article-title":"A novel approach to prepare etoposide-loaded poly (N-vinyl caprolactam-co-methylmethacrylate) copolymeric nanoparticles and their controlled release studies","volume":"127","author":"Shah","year":"2013","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.ejpb.2024.114239_b0070","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.biomaterials.2009.09.033","article-title":"Enhanced efficacy of local etoposide delivery by poly (ether-anhydride) particles against small cell lung cancer in vivo","volume":"31","author":"Tang","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114239_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-022-02329-2","article-title":"Formulation and physicochemical and biological characterization of etoposide-loaded submicron emulsions with biosurfactant of sophorolipids","volume":"23","author":"Ma","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2024.114239_b0080","first-page":"3987","article-title":"Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway","volume":"2014","author":"Jiao","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2024.114239_b0085","first-page":"656","article-title":"Inhalational System for etoposide liposomes: formulation development and in vitro deposition","volume":"73","author":"Parmar","year":"2012","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114239_b0090","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3906\/sag-1412-67","article-title":"Efficacy of pegylated liposomal etoposide nanoparticles on breast cancer cell lines","volume":"46","author":"Mehrabi","year":"2016","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.ejpb.2024.114239_b0095","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1080\/21691401.2019.1646265","article-title":"Preparation, characterization and in vitro evaluation of PEGylated nanoliposomal containing etoposide on lung cancer","volume":"47","author":"Zare","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.ejpb.2024.114239_b0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijpharm.2015.08.043","article-title":"Which polymer is more suitable for etoposide: A comparison between two kinds of drug loaded polymeric micelles in vitro and in vivo?","volume":"495","author":"Chen","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114239_b0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3109\/10717541003720688","article-title":"Etoposide-loaded biodegradable amphiphilic methoxy (poly ethylene glycol) and poly (epsilon caprolactone) copolymeric micelles as drug delivery vehicle for cancer therapy","volume":"17","author":"Mohanty","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114239_b0110","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3390\/ijms24032643","article-title":"Liposomes for tumor targeted therapy: a review","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114239_b0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nnano.2017.67","article-title":"The evolving landscape of drug products containing nanomaterials in the United States","volume":"12","author":"D'Mello","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114239_b0120","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2024.114239_b0125","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2013.11.016","article-title":"Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery","volume":"174","author":"Park","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114239_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076615","article-title":"Liposomes in Cancer Therapy: How Did We Start and Where Are We Now","volume":"24","author":"Fulton","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114239_b0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000056090","article-title":"Encapsulation in cationic liposomes enhances antitumour efficacy and reduces the toxicity of etoposide, a topo-isomerase II inhibitor","volume":"62","author":"Sengupta","year":"2001","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejpb.2024.114239_b0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2478\/acph-2022-0006","article-title":"Optimizing glycerosome formulations via an orthogonal experimental design to enhance transdermal triptolide delivery","volume":"72","author":"Zhu","year":"2022","journal-title":"Acta. Pharm."},{"key":"10.1016\/j.ejpb.2024.114239_b0145","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2147\/IJN.S157746","article-title":"Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro\/vivo evaluation","volume":"13","author":"Kanqiu","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejpb.2024.114239_b0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ejhpharm-2018-001571","article-title":"Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg\/mL in polyolefin bags","volume":"27","author":"Elise","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.ejpb.2024.114239_b0155","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2024.114239_b0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2004.07.045","article-title":"The effects of lyophilization on the stability of liposomes containing 5-FU","volume":"291","author":"Glavas-Dodov","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114239_b0165","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jconrel.2009.10.024","article-title":"An overview of liposome lyophilization and its future potential","volume":"142","author":"Chen","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114239_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodres.2023.112608","article-title":"Specific protection mechanism of oligosaccharides on liposomes during freeze-drying","volume":"166","author":"Deng","year":"2023","journal-title":"Food Res. Int."},{"key":"10.1016\/j.ejpb.2024.114239_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jphp.12489","article-title":"Influence of type and proportion of lyoprotectants on lyophilized ginsenoside Rg3 liposomes","volume":"68","author":"Li","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114239_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113372","article-title":"Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems","volume":"217","author":"Fu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2024.114239_b0185","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.xphs.2021.11.020","article-title":"Effect of Doxorubicin release rate from polyethylene glycol-modified liposome on anti-tumor activity in B16-BL6 tumor-bearing mice","volume":"111","author":"Maruyama","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114239_b0190","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/17425247.2020.1737672","article-title":"The latest advances of cisplatin liposomal formulations: essentials for preparation and analysis","volume":"17","author":"Zahednezhad","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114239_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.623760","article-title":"Triggered drug release from liposomes: exploiting the outer and inner tumor environment","volume":"11","author":"Franco","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114239_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-3155-11-26","article-title":"Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle","volume":"11","author":"Saptarshi","year":"2013","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2024.114239_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119077","article-title":"Quantification of phospholipid degradation products in liposomal pharmaceutical formulations by ultra performance liquid chromatography-mass spectrometry (UPLC-MS)","volume":"578","author":"Siriwardane","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114239_b0210","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.2147\/DDDT.S296253","article-title":"Transferrin-decorated protein-lipid hybrid nanoparticle efficiently delivers cisplatin and docetaxel for targeted lung cancer treatment","volume":"15","author":"Mao","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejpb.2024.114239_b0215","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.332","article-title":"Robust high-throughput kinetic analysis of apoptosis with real-time high-content live-cell imaging","volume":"7","author":"Gelles","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejpb.2024.114239_b0220","doi-asserted-by":"crossref","DOI":"10.15252\/msb.202211490","article-title":"Multisite assessment of reproducibility in high-content cell migration imaging data","volume":"19","author":"Hu","year":"2023","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.ejpb.2024.114239_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201901223","article-title":"Size-dependent EPR effect of polymeric nanoparticles on tumor targeting","volume":"9","author":"Kang","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ejpb.2024.114239_b0230","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114239_b0235","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/adfm.201404484","article-title":"pH-and NIR light-responsive micelles with hyperthermia-triggered tumor penetration and cytoplasm drug release to reverse doxorubicin resistance in breast cancer","volume":"25","author":"Yu","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejpb.2024.114239_b0240","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2018.08.002","article-title":"Degradable poly (ethylene glycol)(PEG)-based hydrogels for spatiotemporal control of siRNA\/nanoparticle delivery","volume":"287","author":"Wang","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114239_b0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2023.10.023","article-title":"Ginsenoside Rg3 endows liposomes with prolonged blood circulation and reduced accelerated blood clearance","volume":"364","author":"Xia","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114239_b0250","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2022.12.050","article-title":"Pre-treatment of oncolytic reovirus improves tumor accumulation and intratumoral distribution of PEG-liposomes","volume":"354","author":"Eguchi","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114239_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2022.119402","article-title":"pH\/reduction dual-responsive hyaluronic acid-podophyllotoxin prodrug micelles for tumor targeted delivery","volume":"288","author":"Li","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2024.114239_b0260","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/17425247.2011.553218","article-title":"Bone marrow-targeted liposomal carriers","volume":"8","author":"Sou","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114239_b0265","first-page":"21","article-title":"A new formulation of Tc-99m minimicroaggregated albumin for marrow imaging: comparison with other colloids, In-111 and Fe-59","volume":"23","author":"McAfee","year":"1982","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejpb.2024.114239_b0270","first-page":"173","article-title":"Drug-loaded nanoparticles : preparation methods and drug targeting issues","volume":"39","author":"Allemann","year":"1993","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124000651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124000651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:54:26Z","timestamp":1760547266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124000651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":54,"alternative-id":["S0939641124000651"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114239","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preparation of etoposide liposomes for enhancing antitumor efficacy on small cell lung cancer and reducing hematotoxicity of drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114239"}}